Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MariMed Inc. filings document formal disclosures for a cannabis consumer products and retail operator, including annual-meeting governance, operating results and material capital-structure agreements. Recent Form 8-K reports furnish quarterly and annual financial results and describe the restructuring of the company's Series B Convertible Preferred Stock obligation, including related debt and equity components.
Proxy materials disclose stockholder meeting procedures and board-governance matters. The filings also identify MariMed's emerging growth company status and provide public records for transactions, obligations and reporting events connected to its cannabis brand, wholesale distribution and dispensary operations.
MariMed Inc.'s Chief Operating Officer Timothy Shaw reported recent stock transactions. On December 12, 2025 he purchased 45,455 shares of common stock at $0.1071 per share. On December 15, 2025, 81,772 restricted stock units vested and converted into common shares, and 24,001 shares were withheld by the company to satisfy tax withholding obligations at $0.1071 per share.
After these transactions, he directly beneficially owned 9,294,541 shares of MariMed common stock. An additional 2,000,000 shares are held indirectly through the Shaw Family Trust for the benefit of his children, for which he disclaims beneficial ownership, and no restricted stock units remain unvested under the May 23, 2025 grant.
MariMed Inc.'s Chief Commercial Officer reported routine equity compensation activity. On 12/08/2025, 54,000 restricted stock units (RSUs) converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held shares to 838,925.
On the same date, 15,850 shares of common stock were withheld by MariMed at a price of $0.0824 per share to cover tax obligations related to the RSU vesting, leaving the officer with 823,075 shares held directly after these transactions. The RSUs convert to common stock on a one-for-one basis.
The filing notes that these RSUs were originally granted on June 8, 2023, and that the remaining 54,000 RSUs from this grant are scheduled to vest on June 8, 2026, under an award agreement between MariMed and the reporting officer.
MariMed Inc. director equity compensation update: Director Edward Gildea reported receiving 247,385 restricted stock units (RSUs) of MariMed Inc. common stock on December 5, 2025. These RSUs convert to common shares on a one-for-one basis and are scheduled to vest in full on December 15, 2025 under the terms of his award agreement with the company. The filing states that the RSUs were granted in lieu of cash for a portion of his fees for serving on the Board of Directors. Following this grant, Gildea is shown as beneficially owning 657,823 shares of MariMed common stock directly, and 247,385 derivative securities in the form of RSUs.
MariMed Inc. director David R. Allen reported an equity compensation grant in the form of restricted stock units (RSUs). On December 5, 2025, he received 176,389 RSUs, each of which converts into one share of MariMed common stock on a one-for-one basis. These RSUs were granted in lieu of cash for a portion of his fees for serving on the company’s Board of Directors.
The RSUs vest in full on December 15, 2025, according to the award agreement between MariMed and Allen. After this grant, he directly beneficially owned 299,755 shares of MariMed common stock and 176,389 RSUs, all held directly.
MariMed Inc. director reports new stock-based compensation grant
A MariMed Inc. (MRMD) director filed a Form 4 disclosing an award of 166,985 restricted stock units (RSUs) on December 5, 2025. Each RSU converts into one share of MariMed common stock, and the award vests in full on December 15, 2025 under the terms of the award agreement. The RSUs were granted in lieu of cash for a portion of the director’s board fees, meaning the director chose to receive equity instead of part of the normal cash compensation. Following this grant, the director reports 315,686 shares of common stock held directly and 166,985 RSUs directly beneficially owned. This filing highlights ongoing use of equity-based compensation to align director pay with company performance.
MariMed Inc. (MRMD) reported an insider equity transaction by its Chief Commercial Officer, Ryan Crandall. On 11/29/2025, Crandall exercised 75,000 restricted stock units (RSUs), which converted into an equal number of common shares at an exercise price of $0 per share. RSUs are a form of stock-based compensation that turn into common stock as they vest.
To cover tax withholding tied to this vesting, 22,013 common shares were withheld at a price of $0.0896 per share. After these transactions, Crandall beneficially owned 784,925 shares of MariMed common stock directly. The RSUs exercised came from a grant originally made on November 29, 2024, with the remaining RSUs from that grant scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027 and November 29, 2027.
MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported equity transactions dated 11/29/2025. He exercised 93,750 restricted stock units (RSUs), which converted into the same number of common shares at an exercise price of $0, and then had 27,516 shares of common stock withheld at $0.0896 per share to cover tax obligations related to the RSU vesting.
After these transactions, Levine directly beneficially owns 21,072,715 shares of MariMed common stock and has an additional 6,684,640 shares held indirectly through the Jon Levine Family Trust, for which he disclaims beneficial ownership. He also continues to hold 187,500 RSUs, from a grant made on November 29, 2024, that are scheduled to vest in four equal installments between May 29, 2026 and November 29, 2027.
MariMed Inc. Chief Operating Officer Timothy Shaw reported equity transactions involving company stock. On 11/29/2025, 81,250 restricted stock units (RSUs) converted into the same number of MariMed common shares at an exercise price of $0, increasing his directly held shares. On the same date, 23,847 common shares were withheld by MariMed at a price of $0.0896 per share to cover tax obligations tied to the RSU vesting. After these transactions, Shaw directly owned 9,191,315 shares of common stock.
In addition, 2,000,000 MariMed shares are held indirectly through the Shaw Family Trust, an irrevocable trust for his children, for which his spouse is trustee and as to which he disclaims beneficial ownership. The RSUs that vested on November 29, 2025 were part of a grant made on November 29, 2024, with the remaining RSUs from that grant scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027, and November 29, 2027.
MariMed (MRMD) President & CEO Jon R. Levine reported equity award activity. On November 7, 2025, 75,000 RSUs converted into common stock (Code M) at $0, and 22,013 shares were withheld to satisfy taxes (Code F) at $0.097.
Following these transactions, he holds 21,006,481 shares directly and 6,684,640 shares indirectly by the Jon Levine Family Trust. 150,000 RSUs remain outstanding, scheduled to vest in equal installments on May 7, 2026 and November 7, 2026.
MariMed Inc. (MRMD) reported Q3 2025 results. Revenue was $40,764,000 with gross profit of $16,363,000. The quarter showed a net loss of $2,941,000 as interest expense and a $2,759,000 tax provision offset operating income of $1,599,000. Adjusted EBITDA was $5,139,000.
Year to date, revenue totaled $118,176,000 with a net loss of $9,815,000. Cash and equivalents were $6,596,000, and net cash provided by operating activities was $4,266,000. Mortgages and notes payable totaled $73,186,000, including $56,324,000 under the CREM loan. Shares outstanding were 394,452,517 as of September 30, 2025; 395,073,625 were outstanding as of November 3, 2025.
The First State Compassion Center acquisition closed March 1, 2025 and contributed $3,900,000 of revenue and $2,400,000 of net income in Q3. In the quarter, 1,155,274 Series C preferred shares converted into 5,776,370 common shares. The company later announced an exit from Missouri operations effective October 28, 2025.